TherapeuticsMD (TXMD) Prices $30 Million Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- US stock futures slip ahead of inflation report
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil gains as stalled US-Iran talks trump supply recovery
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Wells Fargo raises oil price targets citing ongoing supply risks
TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock
November 10, 2020 8:58 AM ESTBOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock for gross proceeds of $30 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by TherapeuticsMD. The offering is expected to close on or about November 12, 2020, subject to customary closing conditions. In addition, TherapeuticsMD has granted the underwriter a 30-day option to purchase up to approximately 3.5 million additional shares of common stock.
Cantor Fitzgerald & Co. is acting as sole bookrunning... More
TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
November 9, 2020 4:01 PM ESTBOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the offering. All of the shares in the offering are to be sold by TherapeuticsMD.
Cantor Fitzgerald & Co. is acting as sole bookrunning manager for the offering.
TherapeuticsMD intends to use the net proceeds from the offering for commercialization of its three FDA-approved products, IMVEXXY® (estradiol... More
